Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival

Multiple Myeloma (MM)

Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation

Blood Cancer J

Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Kebriaei P, Aljawai Y, Khan HN, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH

doi: 10.1038/s41408-024-01062-2

Multiple Myeloma (MM)

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma

J Clin Oncol

Lasa M, Notarfranchi L, Agullo C, Gonzalez C, Castro S, Perez JJ, Burgos L, Guerrero C, Calasanz MJ, Flores-Montero J, Oriol A, Bargay J, Rios R, Cabañas V, Cabrera C, Martinez-Martinez R, Encinas C, De Arriba F, Hernandez MT, Palomera L, Orfao A, Martinez-Lopez J, Mateos MV, San-Miguel J, Lahuerta JJ, Rosiñol L, Blade J, Cedena MT, Puig N, Paiva B, PETHEMA/GEM Cooperative Group

doi: 10.1200/JCO.24.00635

Multiple Myeloma (MM)

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Lancet Haematol

Cook G, Ashcroft AJ, Senior E, Olivier C, Hockaday A, Richards J, Cavenagh JD, Snowden JA, Drayson MT, de Tute R, Roberts L, Owen RG, Yong K, Garg M, Boyd K, Sati H, Gillson S, Cook M, Cairns DA, Parrish C, United Kingdom Myeloma Research Alliance

doi: 10.1016/S2352-3026(24)00249-7

Multiple Myeloma (MM)

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Lancet Oncol

Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuillème S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P, Intergroupe Francophone du Myélome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators

doi: 10.1016/S1470-2045(24)00282-1

Multiple Myeloma (MM)

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial

J Clin Oncol

Mai EK, Bertsch U, Pozek E, Fenk R, Besemer B, Hanoun C, Schroers R, von Metzler I, Hänel M, Mann C, Leypoldt LB, Heilmeier B, Huhn S, Vogel SK, Hundemer M, Scheid C, Blau IW, Luntz S, Weinhold N, Tichy D, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Shumilov E, Knauf W, Michel CS, Geer T, Riesenberg H, Lutz C, Raab MS, Benner A, Hoffmann M, Weisel KC, Salwender HJ, Goldschmidt H, German-Speaking Myeloma Multicenter Group (GMMG) HD7 Investigators, German-speaking Myeloma Multicenter Group (GMMG) HD7

doi: 10.1200/JCO-24-02266

Multiple Myeloma (MM)

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Blood Cancer J

Derman BA, Major A, Cooperrider J, Jiang K, Ramsland A, Karrison T, Kubicki T, Jakubowiak AJ

doi: 10.1038/s41408-024-01156-x

Leukemia

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study

Leukemia

Ortí G, Peczynski C, Boreland W, O'Reilly M, von Bonin M, Balduzzi A, Besley C, Kalwak K, Ryhänen S, Güngör T, Wynn RF, Bader P, Mielke S, Blaise D, Amrolia P, Yakoub-Agha I, Calkoen F, Schubert ML, Potter V, Pichler H, Kröger N, Kwon M, Sengeloev H, Torrent A, Chalandon Y, van Gorkom G, Koenecke C, Graham C, Schoemans H, Moiseev I, Penack O, Peric Z

doi: 10.1038/s41375-024-02467-5

Multiple Myeloma (MM)

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma

Blood

Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, Einsele H, Goldschmidt H, Knop S, Li C, Mellqvist UH, McFadden I, Oprea C, Ross JA, Talpes M, Hydren J, Ahlstrom J, Kazandjian D, Zhang R, Marti GE MD, PhD, Devlin SM, Weinhold N, Stetler-Stevenson M

doi: 10.1182/blood.2024024371

Multiple Myeloma (MM)

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Blood

Badros AZ, Foster L, Anderson LD Jr, Chaulagain CP, Pettijohn EM, Cowan AJ, Costello CL, Larson S, Sborov DW, Shain KH, Silbermann R, Shah N, Chung A, Krevvata M, Pei H, Patel S, Khare V, Cortoos A, Carson R, Lin T, Voorhees PM

doi: 10.1182/blood.2024025746

Related content

Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation

Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma

Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell transplantation (Myeloma XII [ACCoRD]): interim analysis of a multicentre, open-label, randomised, phase 3 trial

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Graft-versus-host disease after anti-CD19 chimeric antigen receptor T-cell therapy following allogeneic hematopoietic cell transplantation: a transplant complications and paediatric diseases working parties joint EBMT study

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical endpoint for multiple myeloma

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study